Marcial Delgado-Fernández , Juan Diego Ruiz-Mesa , Almudena Rojas-González , Gracia Mar García-Gemar , Ana Fuentes-López , Adolfo de Salazar-González , Federico García-García
{"title":"Fresh frozen plasma for neutralizing SARS-CoV-2: “An exploratory cross-sectional study and review of the state of the art”","authors":"Marcial Delgado-Fernández , Juan Diego Ruiz-Mesa , Almudena Rojas-González , Gracia Mar García-Gemar , Ana Fuentes-López , Adolfo de Salazar-González , Federico García-García","doi":"10.1016/j.eimc.2025.03.005","DOIUrl":null,"url":null,"abstract":"<div><div>Restitution of humoral immunodeficiency is essential to clear SARS-CoV-2. Intravenous unspecific immunoglobulins are expensive and restricted. So recently donated fresh frozen plasma (FFP) could be useful in this scenario but, are all units neutralizing against SARS-CoV-2?</div><div>We explored this on 52 donations obtained from “Centro de Transfusión, Tejidos y Células de Málaga, Spain”, from April to June 2022. Donors status about SARS-CoV-2 previous infection or vaccination was unknown. Neutralizing activity (at dilutions<!--> <!-->≥<!--> <!-->1/160) against real Delta (not circulating), BA.2 (dominant circulating variant), BA.5 (irrupting variant), and BQ.1.1 and XBB.1.5 (not circulating yet) was determined.</div><div>Higher anti-Spike IgG antibodies cut-offs predicted efficacy of FFP. Different cut-offs have been reported in the literature, but all papers have in common that levels over the higher range of quantification can predict neutralizing activity of recently donated FFP against circulating variants of concern, if used early after donation, not requiring clinical data from donors.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 5","pages":"Pages 282-290"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213005X25000886","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Restitution of humoral immunodeficiency is essential to clear SARS-CoV-2. Intravenous unspecific immunoglobulins are expensive and restricted. So recently donated fresh frozen plasma (FFP) could be useful in this scenario but, are all units neutralizing against SARS-CoV-2?
We explored this on 52 donations obtained from “Centro de Transfusión, Tejidos y Células de Málaga, Spain”, from April to June 2022. Donors status about SARS-CoV-2 previous infection or vaccination was unknown. Neutralizing activity (at dilutions ≥ 1/160) against real Delta (not circulating), BA.2 (dominant circulating variant), BA.5 (irrupting variant), and BQ.1.1 and XBB.1.5 (not circulating yet) was determined.
Higher anti-Spike IgG antibodies cut-offs predicted efficacy of FFP. Different cut-offs have been reported in the literature, but all papers have in common that levels over the higher range of quantification can predict neutralizing activity of recently donated FFP against circulating variants of concern, if used early after donation, not requiring clinical data from donors.
体液免疫缺陷的恢复是清除SARS-CoV-2的必要条件。静脉注射非特异性免疫球蛋白既昂贵又有局限性。因此,最近捐赠的新鲜冷冻血浆(FFP)在这种情况下可能有用,但是,所有单位都能中和SARS-CoV-2吗?我们对2022年4月至6月从“西班牙Tejidos y csamlulas de Málaga中心”获得的52份捐赠进行了探讨。供体既往感染或接种情况不详。测定了对真实δ(不循环)、BA.2(优势循环变体)、BA.5(突变变体)、BQ.1.1和XBB.1.5(尚未循环)的中和活性(稀释度≥1/160)。较高的抗刺突IgG抗体截断率预测FFP的疗效。文献中报道了不同的截止值,但所有论文都有一个共同点,即如果在捐赠后早期使用,在不需要捐赠者临床数据的情况下,高于较高量化范围的水平可以预测最近捐赠的FFP对关注的循环变体的中和活性。
期刊介绍:
Hoy está universalmente reconocida la renovada y creciente importancia de la patología infecciosa: aparición de nuevos agentes patógenos, de cepas resistentes, de procesos con expresión clínica hasta ahora desconocida, de cuadros de una gran complejidad. Paralelamente, la Microbiología y la Infectología Clínicas han experimentado un gran desarrollo como respuesta al reto planteado por la actual patología infecciosa. Enfermedades Infecciosas y Microbiología Clínica es la Publicación Oficial de la Sociedad Española SEIMC. Cumple con la garantía científica de esta Sociedad, la doble función de difundir trabajos de investigación, tanto clínicos como microbiológicos, referidos a la patología infecciosa, y contribuye a la formación continuada de los interesados en aquella patología mediante artículos orientados a ese fin y elaborados por autores de la mayor calificación invitados por la revista.